The EAHP
Thursday 22 March 2018
Daily dose
Information that makes you feel good! CHECK THE ELECTRONIC VERSION
CONGRESS AGENDA Full programme of activities
Page 2
EAHP SURVEY Survey activities & results
KabiHelp Shaping Tomorrow in PN Compounding
KEYNOTE 1 PREVIEW
New PN Compounder from Fresenius Kabi
A fact–based view on global health and infectious diseases
Live Demos Presented by KabiHelp Experts
Page 6
Page 4
Wednesday, 21 March 2018 11:00 | 14:00 | 16:30 | 19:00
Mariona Ribó
Hospital pharmacists: show us what you can do!
H
ospital Pharmacists – show us what you can do! is the final title of the Gothenburg congress. During the first discussions and brainstorm sessions the Scientific Committee of EAHP posed the question “what would happen if all hospital Pharmacists would go on holidays at the same time’…. Probably nothing during the first three months of their absence.
Often than the question arises “but what are all these people doing”?
We are excellent in organising our own work. Often, we arrange it in a way that we can be missed for several hours up to several days. After that some people will start asking “where is the pharmacist”? And in most of the cases the pharmacist is working in his/her room, quietly and focussed on the problem that has been communicated to him/ her. He/she is there, but hardly visible.
But there is more. I will mention here the clinical side of our work. The work of the hospital pharmacist is slowly moving into the area of patient care. And we do that not alone. In many hospitals the (clinical) pharmacist is a member of the medical team. We were not accepted because of our looks, but we are respected because of our knowledge of the pharmacological and clinical properties of the medication, on top of the basic chemical, biological and physical knowledge. But to get known within the hospital is not an easy thing to do, especially because we are not yet fully aware of the marketing strategies we could use
It is not unusual that, when I explain to other people where I work and what I do, they are surprised that my department, the department of Clinical Pharmacy and Toxicology, is a department with more than 130 employees.
And that hits our Achilles heel. We are not known in the hospital as a member of the team that takes care of the patient. Our contribution is – to their knowledge – limited to the preparation and distribution of drugs inside the hospital. And we do that the best way we can.
in our daily practice.
Thursday, 22 March 2018 11:00 | 14:15 | 17:00
r Visit ou ee s o t Booth lp e iH b Ka
Friday, 23 March 2018 11:00
This year’s Congress program should offer you as participant the tools which enable you to setup your own marketing strategy in your hospital. One of the keynote lectures is dedicated to marketing principles that can be used in your day–to–day work. Participation in medical ethical committees and clinical trial boards will show to other stakeholders what the added value of a hospital pharmacist to their team can be. Besides the seminars on methodological actions, the program offers subjects that are relevant for our work as hospital pharmacist. Covered by the European Statements of Hospital Pharmacy the seminars of the 23rd Congress offer a wide variety of subjects to attribute to, like participation in the drugs and therapeutics committee, clinical trials in haemato–oncology in paediatrics, guideline implementation and drug administration. Kees Neef – EAHP Director of Education, Science and Research
Meet the Expert! TDPT-IL-00080
Dr. Paul Sessink Handling Antibiotics with Tevadaptor® Booth #48 (Hall B)
Tevadaptor® is scientifically validated with repeated proven performance
Wednesday, March 21st, 2018 12:00-13:00 17:00-18:00 Thursday, March 22nd, 2018 09:30-10:30 14:00-15:00
Visit our Booth #48 to view Antibiotics wipe testing results and elastomer integrity testing results
Poster Session (Hall A) During coffee breaks
www.tevadaptor.com
23rd Congress of the EAHP
2
THURSDAY, 22 MARCH DATE/TIME MEETINGS/EVENTS
ROOM
06.30 – 17.00
Registration opens (individuals, groups and exhibitors)
Entrance No 2
08.30 – 17.30
Exhibition opens
Hall B
07.30 – 09.00
Synergy breakfast event – The power of automation (sponsored by an educational grant from Omnicell) Hall C G. Honeywell; G Henneré; M. J. Tamés
09.00 – 10.30
Synergy Interactive Session – Anticoagulation – from theory to practice (sponsored by an education grant from Bayer) K. Malá; S. Steurbaut; B. van den Bemt
09.00 – 10.30
Seminars
09.00 – 10.30
H1
Seminar IG3 – The effective pharmacists – The team member A. Sinclair; P. Mirbod
F2+F3
Seminar PC3 – Hospital pharmacists involved in ATPM and in Risk Assessment A. De Goede; K. Saadat
G3
Seminar PC2 – Hospital mergers and the centralisation of production services A. Vermes; S. Crauste–Manciet
G1+G2
Seminar CPS2 – Providing pharmaceutical care for patients admitted to their own bedroom M. Rom; C. Endrell
A5
Seminar PQ1 – Materiovigilance (UDI – tracing – reporting) V. Nys; B. Lambaux
F5
Seminar SPD1 – Medicines shortages – A reality check? T. Hoppe–Tichy; N. Linde–Laursen
A3
Industry sponsored satellites Fresenius Kabi Deutschland GmbH “Parenteral Nutrition: The Total Picture – Overview of Current Practices in PN Compounding”
H2
MSD “Clinical and Economic Implications of the Most Serious Infections Caused by Resistant Pseudomonas and ESBL Producers: Role of New Options”
G4
Amgen “Hospital pharmacists at the forefront – Evaluating and implementing biosimilars”
F4
10.30 – 11.30
Coffee break and attended posters
Hall A / Hall B
11.00 – 12.00
Keynote 2 – We have a dream! C. McKay; J. Underhill
Hall C
12.00 – 13.30
Seminars
12.00 – 13.30
Seminar IG2 – The productive pharmacist – Process and workforce planning V. Zardet; M. Frachette
F5
Seminar ER3 – The art of writing an abstract and getting in accepted G. Stemer; T. Hoppe–Tichy
G3
Seminar PC1 – Clinical trial regulation and ethical committees I. Krämer; C. M. Romeo Casabona
A3
Seminar CPS3 – Antimicrobial stewardship – Growing a positive culture U. Dumpis; J. Thern
G1+G2
Seminar PQ2 – Ready to administer drugs – Is everything under control? S. Sauer; O. Delgado Sánchez
A5
Seminar ER2 – Clinical Pharmacy Services: Absence of evidence is not evidence of absence L.J. Kjeldsen; J. Krska
F2+F3
Workshop 2 – Assessment and clinical importance of pharmacists recommendations H. Toss, U. Gillespie
R2
Seminar PC5 – Presentation and workshop dedicated to the implementation of the Resolution [CM/Res(2016)2] on good reconstitution practices in European hospitals H. Scheepers; P. Le Brun
A4
Synergy Satellite Session Biosimilars in cancer care – the next challenge (financial support was provided by Pfizer Limited as a Medical and Educational Goods and Service) R. Giuliani, P. Cornes; G. Befrits
H2
23rd Congress of the EAHP
12.00 – 13.30
3
Industry sponsored satellites Grünenthal “A new option for treating post–operative pain – Sufentanil sublingual tablet system”
H1
BMS Pfizer Alliance “Non–Vitamin K antagonist Oral Anticoagulants (NOACs): Advancing patient care in stroke preG4 vention and venous thromboembolism” Leo Pharma “Anticoagulation in active cancer: Special considerations”
F4
13.30 – 15.00
Lunch
Hall B
13.45 – 14.15
Bayer – Meet the Expert
14.15 – 14.45
Bayer – Meet the Expert
15.00 – 16.30
Seminars
Hall B – Booth no 26 Hall B – Booth no 26
Seminar IG1 – The efficient pharmacist – Prioritising tasks and designing processes R. Fernandes; A. Jacklin
F2+F3
Seminar PC4 – Quality and risk assessment of medicines for children D. Zanon; A. Lowey
A5
Seminar CPS1 – Managing polypharmacy – Thinking outside the box M. Wilson; C. Morrison
G1+G2
Seminar ER1 – Clinical Trials in Paediatric Haemato–oncology: different ways for HPs to participate M–B. Aretin; F. Engels
G3
Seminar SPD2 – Bridging the efficacy / effectiveness gap A. Gouveia; N. Groessmann
A3
Workshop 1 – The pharmacist’s role in the drugs and therapeutics committee N. Martinez–Lopez de Castro; H. Plet
J2
Workshop 3 – Check of medication appropriateness (COMA): an instrument to implement clinical guidelines in practice R2 T. Van Nieuwenhuyse; C. Quintens 15.00 – 16.30
Synergy Satellite Session The essentials of biologicals – past, present and future (sponsored by an educational grant from Svandoz) Harald H. Sitte; S. Simoens; P. Troein
15.00 – 16.30
16.30 – 17.30
H1
Industry sponsored satellites B. Braun “Economical benefits of short acting spinal anesthetics”
H2
Coffee break
Hall B
SYNERGY EVENT: PREVIEW & SPEAKERS
The power of automation
F
or over a century hospital pharmacists were focused on manual work and logistic burden of compounding and dispensing. To improve patient safety, the focus shifted from product to therapy and the implementation of clinical pharmacy and clinical validation. However, the basic tasks must continue to maintain the highest quality to prevent medication errors. The introduction of automation in the hospital pharmacy could free up people for the new tasks without deterioration of quality. In the distribution process automation is already well established. Picking robots, electronic dispensing cabinets, automated
guided vehicles, pneumatic tubes, single– dose dispensing machines and maybe shortly drones have found their way into the hospital pharmacy. They introduce efficiencies such as faster work rates, reduction in picking error rates and allow implementation of traceability. But they also introduce new possible risks with which the pharmacist has to deal. In our morning Synergy session two colleagues are will be presenting how they organised an automated distribution and elaborate on the benefits and pitfalls of the system. Gillian Honeywell, chief pharmacist in an integrated health organisation on the
Isle of Wight, has a research focus on the impact of technology to free clinical time and reduce waste and believes that automation can add to a safer therapy. She has implemented central and decentral automation. Gaëlle Henneré is a hospital pharmacist in the Robert Ballanger hospital in Paris where she works with automated dispensing cabinets on the wards. She is interested in quality of care and participates in the validation of prescriptions and elaborates on risk management of automated distribution processes.
compounding units, varying from simple in process controls to fully automated compounding robots for cytotoxics. Trusting the patient’s life to a machine requires a validated process and risk management under the responsibility of the hospital pharmacist. Maria–José Tamés is assistant director of pharmacy in the oncology centreer in San Sebastian and has a research focus on compounding of chemotherapy. Her presentation comments on the main issues to consider when planning a transition from manual to automated chemotherapy.
And the rise of the machines continues. Hospitals implement automation in
Thomas De Rijdt – EAHP Scientific Committee Member
23rd Congress of the EAHP
4
POLICY ARTICLE
Medicine Shortages – New survey activity by EAHP aiming to improve patient outcomes
T
he EAHP has been advocating on the issue of medicines shortages and its threat to patient care in hospitals for a number of years on behalf of its members. Apart from raising the awareness of European policy–makers to the medicines shortage problem, EAHP has worked increasingly on expanding the available evidence–base related to the problem. To this end, the association has conducted two surveys – one in 2013 and one in 2014 – to gather data on hospital pharmacists experience with medicines shortages. EAHP’s 2014 survey of hospital pharmacists about medicines shortages was the largest pan–European analysis that surveyed the opinion of healthcare professionals on the topic, with over 600 responses from 36 countries. Key findings included:
•
•
•
•
• •
86% of hospital pharmacists reported that medicines shortages are a current
problem in the hospital they work in, in terms of providing the best care to patients and/or operating the hospital pharmacy; 66% of respondents said that medicines shortages affect their hospital pharmacy on a daily or weekly basis; Antimicrobial agents, oncology products, emergency medicines, cardiovascular medicines and anaesthetic agents are the top affected; 75.4% of hospital pharmacists either agreed or strongly agreed with the statement “medicines shortages in my hospital are having a negative impact on patient care.”; 63% of hospital pharmacists estimate that the typical medicines shortage normally lasts for a number of weeks; Reported impacts for patients include delayed or interrupted chemotherapy treatment, unnecessary experience by
EAHP 2018 MEDICINE SHORTAGES SURVEY OUT NOW! Take the survey and make your voice heard!
patients of side effects, heightened clostridium difficile risk and deterioration in patients’ conditions. To address the medicines shortages problem in a more effective manner, EAHP called for the improvement of transparency, including clearer and better obligations for manufacturers and other supply chain actors to report both current shortages and likely future disruptions to supply. The advocacy work of EAHP to an increase in cooperation with interested partners in advancing potential solutions and remedial measures. Together with manufacturers of medicinal products, parallel distributors, healthcare distributors and pharmacists, the EAHP formed an informal working group in 2015 and published a set of recommendations in early 2017 calling for greater transparency and availability of medicines shortage data, early detection and assessment of potential shortages, consistency of reporting, increased access to the information available across all parts of the supply chain, improved data infrastructure, and collaborative stakeholder governance processes. This call for action by supply chain actors was again brought to the attention of Health Ministers ahead of the Bulgarian Presidency event ‘Health as the Real Winner: Presidency conference on options to provide better medicines for all’ in early March 2018.
Medicines Shortages Report. On 19th March 2018, a survey activity was launched with the aim to provide a clearer picture on the impact that medicines shortages have had on the work carried out by hospital pharmacists. The survey will gather data on •
• • • •
•
The current nature of medicines shortages problems in Europe, including their prevalence; The most common types of shortages; Their impact on patient care and hospital pharmacy services; Existing national mechanisms for dealing with or monitoring shortages; How hospital pharmacists typically manage the problems shortages cause; and, Hospital pharmacist views on proposed policy solutions.
European Hospital pharmacists are invited to participate until 11th June 2018 in the survey activity (for more information scan the QR Code on the right–hand side). Through the collection of data on the prevalence of shortages, types of shortages and length of shortages, EAHP aspires to contribute to charting the current challenges hospital pharmacists face due to medicines shortages with an updated analytical report. Stephanie Kohl – EAHP Policy Officer
As data on the prevalence, nature and impact for patient care of medicines supply shortages is still lacking, EAHP saw a need for a follow–up investigation to its 2014
SYNERGY EVENT: PREVIEW & SPEAKERS
Visit the Cyber Cafe! The essentials of biologicals: past, present and future
S
ince several decades many therapeutic approaches utilise biologicals as treatment strategies for severalnumerous diseases. Hospital pharmacists have learned how to deal with them at the selection, use and monitoring level. It is time to look at the experience accumulated, in order to summarize pros and cons of biologicals and biosimilars: what knowledge is needed, which challenges are still to be pointed out, what are the opportunities. This is the aim of the synergy seminar on “Tthe essential of biologicals – past, present and future”. So,: check what you know and what is needed to know.
Prof Dr Harald H. Sitte will be focusing in his presentation on biologicals and biosimilars, scientific aspects of production and quality control. Health economics of biologicals and biosimilars the essentials will be covered by Prof Dr Steven Simoens, before Mr Per Troein will close with information on leveraging biosimilars for better access and lower costs.
biosimilars bring from the economic standpoint, and how to integrate this information for better choices at the strategic and hospital direction level. Moreover, the issues of switching and interchangeability of biologicals will have been outlined to you.
Fill in the online evaluation forms of the sessions you attend to be part of the prize draw for free registration for the next EAHP Congress
Practical Pharmaceutics • Covering prescription – product design – production - logistics • A solid base for problem solving skills • Strong on example formulations • Natural links between industrial production and preparation in pharmacies • Supports the right use of medicinal products by patients
‘An indispensable knowledge base for the production of high quality pharmaceutical preparations’
Share your opinion on the principles of switching between biologicals from the clinical standpoint.
Daan JA Crommelin
‘Written for practitioners by practitioners’ Joan Peppard
After this Synergy Satellite you will We will do it with experts in the field: learn which are the things you have to know more aboutfrom the production and quality control side, in order to make well informed choices. You will have learned Listen about the opportunity that biologicals and
‘An excellent reference source to assist our daily work’ Roberto Frontini
If biologicals and biosimilars are part of your daily practice, come to this synergy session to check if you really know everything about the topic! Francesca Venturini – EAHP Scientific Committee Member
3000 books sold all over the world Approx. price: e-book €95, hardcover €128, paperback student edition €118. Buy at Springer.com, also for abstracts, citations and reviews. More details: www.eahp.eu/publications
Adv. Recepteerkunde 2018 128 x 175 mm.indd 1
27-02-18 14:02
23rd Congress of the EAHP
5
REPORT OF SYNERGY SATELLITE EVENT
EAHP 2018 Available in app stores for IOS, Android devices and on the Web
Biosimilars in breast cancer – the next challenge
T
he Synergy Satellite Event: ‘Biosimilars in breast cancer – the next challenge’, sponsored by an educational grant from Amgen, was held yesterday at midday, during the first day of the 23rd Congress of EAHP in Gothenburg.
real time! After each presentation, participants were allowed to reply to the same questions again, allowing for a comparison of pre–and post–presentation results, clearly reflecting the initial knowledge gap regarding biosimilars.
The event, featuring three seminars, began with participants taking part in a dynamic voting exercise designed to test their knowledge on breast cancer therapy, including common misconceptions regarding changing trends in first–line therapy. By viewing the voting results on the big screen above the panel, participants had the chance to compare their answers with those of other hospital pharmacists – in
The first presentation, by Joao Goncalves and titled ‘The Impact of biosimilar quality for clinical safety and efficacy: the case of Trastuzumab’ demonstrated the paradigm shift in addressing oncology biosimilars, also carrying out an in–depth analysis on the comparability of originators and biosimilars. A specific emphasis was placed on the frequent shortages of oncology medicines, linking it to the need to take into account the long–term stability of biologics. This was followed by a presentation by Hanne Rolighed Christensen, titled ‘Considerations and reflections concerning implementation of biosimilar MABs in the clinic – focus on Trastuzumab’, outlining the history of biosimilars and current differences in approval mechanisms, exemplified by the fact that the European Medicines Agency has a single approval mechanism while the United States of America has two. Key issues were presented, such as the interchangeability between biosimilars and originators, and switching between biosimilars.
Mariona Ribó
The final presentation, by Rupert Bartsch and titled ‘The evolving landscape of HER2 – directed therapy’, showcased HER2 as a unique success story, indicating that it
Free Wi-Fi service will be available through the congress center. The Wi-Fi network name is “GothiaTowers”and no password is needed
Brought to you by Bayer, EAHP Platinum Partner
is uncommon for a prognostic marker to become a therapeutic target, and pointing out that it has transformed the status of a life–threatening disease into a chronic disease that can be treated. The presentation also covered topics such as neoadjuvant treatments and pointed out that breast cancer is the second most common cause of brain metastases. The event proved very popular, as the plenary room was full, and participants were highly engaged via the interactive voting device. Stay tuned for news on the other Synergy Satellites in our post–Congress issue! Jordi Mallarach – EAHP Policy Team Assistant
THE RIGHT MEDICINE FOR YOUR PATIENT IS UNAVAILABLE. WE GET IT.
TRUSTED BY PHARMACISTS FOR THE PROVISION OF ACCESS TO UNLICENSED MEDICINES When the right medicine for your patient is not licensed in your country, experiencing a shortage or has been discontinued, access to unlicensed medicines plays an essential role in ensuring the best possible patient outcome. Clinigen is the global leader in delivering ethical, compliant and timely access to unlicensed medicines, providing pharmacists with solutions to meet the patient's needs.
VISIT US Stand 21 Exhibition Hall Hall B +44 1932 824000 medicineaccess@clinigengroup.com www.clinigengroup.com
23rd Congress of the EAHP
6
KEYNOTE 1 REVIEW
A fact – based view on global health and infectious diseases
T
he majority of people believe that the world is divided in completely different parts with great gaps between them. But how does one shape theirimageof the world? In the Keynote 1 of the 23rd EAHP Congress of EAHP, Dr Helena Nordenstedt addressed the current demographic trends, developed on their future until 2100, and explained the ongoing global disease panorama shift. Dr Nordenstedt opened the keynote with presenting the fact–based world view which showed;facts are that people are healthier in some places in the world, and less in others. Some diseases are more common in some places, and less in others. She challenged the publiaudiencec to answer three questions
EAHP warmly thanks our industry partners for their continued commitment to supporting the goals of hospital pharmacists
PLATINUM PARTNERS
about global life expectancy, vaccination rates for one year olds, and the projected number of children in the world in 2100. The global average life expectancy is 72 years, 80% of children worldwide are vaccinated against at least one disease, and the projected number of children born in 2100 is 2 billion. Is the world as we currently know it in trouble? She continued by presenting theshowing data for average life expectancy trends in the past 200 years, between the years 1810 and 2009. In thise period, the average life expectancy has more than doubled, from 30 to 72 years. And even though there were big differences between high and low income countries, they have been converging in the past 50 years. The countries are no longer split
CORPORATE PARTNERS
into two distinguished groups.; Tthere is a scale between the extremes, and that scale represents countries that are home to 5 billion of the global population. In line with the shift of life expectancy, the global demographic structure will change significantly until 2100. With more and more people reaching old age, the global population will reach 11 billion, with children representing 2 billion, which is same as they do now. But what about the global disease burden? There is still a significant disparity between the low and high income countries, especially with the distribution of the disease burden. In low income countries, infectious diseases are the biggest burden by far. Moving towards high income countries, the burden is
Mariona Ribó
dramatically shifting towards non–communicable diseases. The interesting fact here is that the burden of non–communicable diseases per person does not change significantly from low to high income countries.; Wwhat changes is the burden of infectious diseases, which is extremely low in high income countries. Dr Nordenstedt concluded the lecture with reiterating the key facts. The global life expectancy rose dramatically, the population increase is stabilising, and NCDs non–communicable diseases are becoming the main cause of death in more and more countries. The gap between the wealthy and the poor parts of the world is decreasing and the world is slowly becoming a better place for everyone. Črtomir Fleisinger – EPSA President
REPORT OF SYNERGY SATELLITE EVENT
Anticoagulation – from theory to practice
T
his excellent theory into practice interactive session is a “must attend” on Thursday 9 am if you did not make it on Wednesday afternoon.
Care Taskforce), presented projects that could be replicated across Europe to improve the care of patients suffering from AF.
Approximately 360.000 new cases of atrial fibrillation (AF) related stroke occur annually in the European Union1. Oral anticoagulant (OAC) therapy reduces the risk of AF–related stroke by 64%, however, still up to 40% of AF patients do not receive OAC2. About 37% of documented chronic AF patients are unaware of their status and only 20% of patients are aware of the benefits of OAC therapy to prevent stroke3. Every day hospital pharmacists will care for patients with AF and with ever increasing usage of direct oral anticoagulants (DOACs) across Europe it is imperative that pharmacists are equipped to help identify patients with anticoagulation and help ensure the appropriateness of therapy. DOACs have the advantage of a wider therapeutic window, fewer drug and food interactions, no need for routine monitoring and more predictable pharmacokinetics but like all high risk medication ” one size does not fit all “. During this session, three pharmacist practitioners members of iPACT (International Pharmacists for Anticoagulation
At the beginning of the session: • Participants felt the top 3 roles for pharmacists caring for patients on anticoagulation were education, adherence, monitoring; • Participants felt uncomfortable dealing with switching anticoagulants and checking manual radial pulses to opportunistically identify atrial fibrillation.
in 2018) to help pharmacists feel more confident about DOAC switching and the dangers of dosing of under or over dosing in patients with increased patient complexity ,age , renal dysfunction and frailty 4. Examples of the iPACT guideline to help improve adherence with DOACs • use of SMS text messaging for patients with non intentional non adherence • use of patient communication models dealing with patient concerns for patients with Intentional non adherence 5. How to reduce errors during transfers of care by ensuring correct documentation of the exact indication and dosing schedule for anticoagulants Of note iPACT are planing a European multi centred trial to look specifically at this crucial stage of the medication usage process and are asking for interested pharmacy departments to contact them via iPACT The session concluded that there is much work to de done in patients with AF and that pharmacists are a crucial member of the healthcare team in the bid to help prevent unavoidable strokes. Steve Williams – Associate Editor, European Journal of Hospital Pharmacy
During the session practical advice and key messages for pharmacists included: 1. How to help with early detection of AF and ongoing referral especially in primary care where patients may not access medical services (useful websites www. knowyourpulse.org and www.ipact.org) 2. Use of the CHADSVAC risk score and the need for collaboration with physicians once AF has been detected in patients 3. Availability of iPACT e learning tool ( due for publication Mariona Ribó
23rd Congress of the EAHP
7
POLICY ARTICLE
EAHP’s annual member gathering at Congress and a heated discussion on FMD EAHP Members’ meeting Like every year, also the 23rd edition of the EAHP Congress is bringing together many hospital pharmacists from all over the world, including EAHP’s 35 member countries. On 21st March, the EAHP Board as well as representatives from our national member associations got together for their annual Members’ Meeting to discuss the latest news on EAHP activities and European matters that affect hospital pharmacy. President Joan Peppard and Project Director Tony West used the opportunity to brief the members on the developments of EAHP’s key projects, the implementation of the European Statements of Hospital Pharmacy and the Common Training Framework (CTF) for a hospital pharmacy specialisation. In addition, the Board leads on antimicrobial resistance, medicines shortages and the Falsified Medicines Directive (FMD) presented the latest developments. The launch of the 2018 Medicines Shortage Survey, the Self–assessment tool and
the Statement Implementation Learning Collaborative programme (SILCC) featured prominently during the meeting which was started off by Vice President Aida Batista with a presentation on the 2017 EAHP survey finds. EAHP members meeting on FMD With the implementation deadline of the Delegated Regulation laying down detailed rules for the safety features appearing on the packaging of medicinal products for human use fast approaching, EAHP saw a need to provide representatives of its national member associations with the opportunity to share best practices and to discuss issues faced by the hospital pharmacy profession. The meeting on the Falsified Medicines Directive (FMD) and its delegated act was joined by Dr Patrizia Tosetti – Policy Officer at the Commission Directorate for Health and Food Safety.
European level together with the European Hospital and Healthcare Federation (HOPE) and as a member of the European Medicines Verification Organisation (EMVO), representatives of national member organisations were provided with the opportunity to share their experiences and to ask questions to Dr Tosetti. The discussion centred around costs incurred by hospital pharmacies, the white list as well as aggregated coding and its advantages. A more extensive report on both the Members’ Meeting and the FMD meeting at Congress will follow in the post– Congress edition of the Daily Dose. Stephanie Kohl – EAHP Policy Officer
After hearing from EAHP about the efforts taken on
ACROSS
2. Where was the previous EAHP Congress? 4. EAHP is working closely on which directive ensuring medicine traceability? 6. The name of the policy publication of EAHP is EU.... 8. Antimicrobial Stewardship helps fight… 11. What solution at stand 29 is helping pharmacists achieve compliance? 12. The brand name of the Compounder Family. You can find the answer in booth number 136. 13. Which therapy increases the risk of CLOTS in cancer patients? 14. Come to BD #65 to discover how to develop a culture of _ _ _ _ _ _ 16. Grifols city of origin. The answer in booth 59! 17. The only official journal of the European Association of Hospital Pharmacists. 18. These medicines can resolve medicine shortages; visit Clinigen, stand 21! 20. Tells you identity and concentration of an intravenous drug in 3 seconds. 21. 25th EAHP Congress is taking place in ____ years.
Crossword Puzzle Complete one of the crossword puzzles included in the Wednesday and Thursday Daily Dose, bring it to the EAHP booth #78 and enter a prize draw to win a free registration for the 24th EAHP Congress in Barcelona (27 – 29 March 2019).
DOWN
1. What is the Generic name of B.Braun short-acting spinal anesthetics-Takipril® and Prilotekal®? 2. Please join one of our Sandoz booth activities (#61) to receive the answer. 3. Haemopharm’s drug reconstitution system brand name. 5. How many API’s has Fagron, booth #52 available in sterile PFS? 6. Unit Dose Done Right. Easiest way to package meds. 7. What is the “I” in ISL stand for? You can find the answer at the hameln booth. 9. Visit booth #2 to discover Accord’s vial protection system. 10. State in which B&W Tek (booth #54) headquarters are located. 15. The next EAHP President will be Petr… 19. Which proteins are recruited and activated by activated JAK proteins1? (4 letters) Try the VR activity at booth 1 to find out.
FULL NAME: EMAIL: R. Shuai K, Liu B. Nat Rev Immunol 2003; 3: 900–911.
1
Unit Dose Done Right
Unit Do se Bar Cod , ing, Pharma c Nursing y & Supply Experts !
• Ultraviolet Inhibitant • Moisture Resistant • Tamper-Evident • Cold Seal • 6 and 12-month Beyond-Use Dating • 1-D and 2-D Bar Coding • Flexible Label and Report Formatting • Multiple Sizes to Fit Your Meds and Storage Needs
Simple. Reliable. Distributed in Europe by Pero’s PEROS LOGO
27/04/10
14:17
Page 1
Please see us at Booth #22
Lyon-France +33.478.627.713 www.peros.fr contact@peros.fr